Effects of rosiglitazone maleate on type 2 diabetes

Chinese Pharmaceutical Journal

Volumn 38, Issue 7, 2003, Pages 511-514

  Liu, Yu ^a   Gao, Xiang Dong ^a   Xing, Wei Fan ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Insulin receptors; Rosiglitazone maleate; Serum insulin; Streptozotocin

Indexed keywords

BLOOD; CELL MEMBRANES; IMMUNOLOGY; INSULIN; LIPIDS;

INSULIN RECEPTORS;

DRUG PRODUCTS;

INSULIN RECEPTOR; ROSIGLITAZONE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFECT; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RADIOIMMUNOLOGY; RAT; SENSITIZATION;

EID: 0042932598     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Lister CA, Boam D, Bretherton-Wall D, et al. Rosiglitazone increases pancreatic islet area, number and insulin content, but not insulin gene expression [J]. Diabetologia, 1998, 41 (Suppl): A660.
2. Finegood DT, McArthur MD, Kojwang D, et al. The PPARγ agonist rosiglitazone (RSG) decreases net loss of pancreatic β-cell mass in Zucker diabetic fally rats [J]. Diabetes, 1999, 48(Suppl): S237.
3. Spiegelman B M. PPAR-gamma: adipogenic regulator and thiazoliadinedione receptor [J]. Deabetes, 1998, 47: 507.
4. Oakes ND, Kennedy CJ, Jenkins AB et al. A new antidiabetic agent, BRL49653, reduces lipid availability and improves insulin action and glucoregulation in the rat [J]. Diabetes, 1994, 43: 1203.
5. Young PW, Cawthome MA, Coyle PJ, et al. Repeal treatment of obese mice with BTL496S3, a new potent insulin sensitizer, enhances insulin action in shite adipocyles, Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling [J]. Diabetes, 1995, 44: 1087.